Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | UGCG | Q16739 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL462999 | 0.84 | MAPK14 (0.50) | MAPK14HSD11B1LMNAALDH1A1KDM4E | |
| SCHEMBL6320610 | 0.80 | MAPK14 (0.61) | MAPK14UGCGHSD11B1SCN5ASCN9A | |
| SCHEMBL900154 | 0.79 | NOTUM (0.44) | MAPK14HSD11B1LMNAALDH1A1MEN1 | |
| SCHEMBL12523393 | 0.79 | CYP17A1 (0.49) | MAPK14UGCGSCN5ASCN9ACYP17A1 | |
| SCHEMBL4300658 | 0.77 | MAPK1 (0.54) | ALDH1A1 | |
| SCHEMBL18172045 | 0.76 | MAPK14 (0.79) | MAPK14UGCGHSD11B1SCN5ASCN9A | |
| SCHEMBL3493407 | 0.75 | MAPK14 (0.58) | MAPK14UGCGHSD11B1SCN5ASCN9A | |
| SCHEMBL2456582 | 0.74 | SMN1; SMN2 (0.51) | MAPK14CYP1A2LMNATP53TSHR | |
| SCHEMBL30785633 | 0.73 | MAPT (0.63) | MAPK14SCN5ASCN9ALMNAALDH1A1 | |
| SCHEMBL6405465 | 0.73 | MAPT (0.63) | MAPK14SCN5ASCN9ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614052-B1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL MYERS SQUIBB CO (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-2614052-B1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL MYERS SQUIBB CO (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-2614052-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | Bristol-Myers Squibb Company (US) | 2013-07-17 | — | — | EP | disclosed |
| US-8362004-B2 | Piperazine analogs as broad-spectrum influenza antivirals | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362004-B2 | Piperazine analogs as broad-spectrum influenza antivirals | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362004-B2 | Piperazine analogs as broad-spectrum influenza antivirals | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| WO-2012033736-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012033736-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | ZC3HAV1, ZC3HAV1L, HCRTR1 | MAPK14 3731/4885UGCG 4712/4885HSD11B1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.